| Theme | Clinical Management of Esophageal Cancer 2017 -- Current Status and Issues | |
|---|---|---|
| Title | Future Perspective of Cancer Immunotherapy | |
| Publish Date | 2017/08 | |
| Author | Takashi Kojima | Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East |
| Author | Tetsuya Nakatsura | Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center |
| [ Summary ] | Development of esophageal squamous cell carcinoma treatment has not progressed sufficiently, and survival has not significantly improved. In recent years, various immunotherapies including immune checkpoint inhibitors, have been reported in diffrent carcinomas, and promising data have been reported in clinical trials with anti‒PD‒1 antibody drugs in esophageal cancer. Similar to other cancers such as malignant melanoma, recovery is also possoble in esophageal cancer. Cleary, esophageal cancer can be controlled. However, the response rate with anti‒PD‒1 antibody alone is only 10‒20 % ; thus, searching for biomarkers to predict the efficacy obtain better response to combination therapy is needed. As such, various clinical trials are being conducted. | |